Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -928119.20x is 491769% below its 4-year average of -188.69x, near the low end of its 4-year range (-928119.20x–5.81x).
As of the fiscal period ended Thursday, March 31, 2022. 369.19% below its 12-month average of -197812.84x.
Reported quarterly interest coverage; no daily interpolation. Q1 FY2022 (2022-03-31): -928119.20x.
INTEREST COVERAGE RATIO
-928119.20x
INTEREST COVERAGE RATIO AVG TTM
-197812.84x
INTEREST COVERAGE RATIO AVG 3Y
-204.64x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-369.19%
CURRENT VS 3Y AVG
-453445.44%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.45x
median of 522 covered companies
CURRENT VS SECTOR MEDIAN
-14389344.96%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$262.92M
Interest Coverage Ratio
-928119.20x
TTM Avg
-197812.84x
3Y Avg
-204.64x
5Y Avg
N/A
Market Cap
$262.66M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.68M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.11M
Interest Coverage Ratio
-1805.60x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$260.79M
Interest Coverage Ratio
-9.79x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.87M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.14M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.00M
Interest Coverage Ratio
-360.54x
TTM Avg
23.12x
3Y Avg
23.12x
5Y Avg
1139.56x
Market Cap
$267.85M
Interest Coverage Ratio
-4.86x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $262.92M | -928119.20x | -197812.84x | -204.64x | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $262.66M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.68M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -1805.60x | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $260.79M | -9.79x | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $265.87M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $258.00M | -360.54x | 23.12x | 23.12x | 1139.56x |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $267.85M | -4.86x | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $257.94M | -530.37x | N/A | N/A | N/A |
Interest Coverage
-928119.2x
Debt/Equity
0.00
Current Ratio
15.82
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2022-03-31 | -928119.20x |
| 2021-12-31 | -31907.98x |
| 2021-09-30 | -28477.96x |
| 2021-06-30 | -336.50x |
| 2021-03-31 | -222.54x |
| 2020-12-31 | -168.21x |
| 2020-09-30 | -96.33x |
| 2020-06-30 | -52.08x |
| 2020-03-31 | -72.73x |
| 2019-12-31 | -54.51x |
| 2019-09-30 | -154.20x |
| 2019-06-30 | -417.16x |
| 2019-03-31 | -472.12x |
| 2018-12-31 | -223.76x |
| 2017-12-31 | 5.81x |
